T1	Participants 64 123	patients with mild-to-moderately-active ulcerative colitis:
T2	Participants 447 676	multicenter study patients with symptoms of acute UC and a baseline Modified Mayo Disease Activity Index (MMDAI) score between 6 and 10, inclusive, with a subscale rating of > or =2 for both rectal bleeding and mucosal appearance
T3	Participants 1053 1106	A total of 249 patients (166 balsalazide, 83 placebo)
T4	Participants 1896 1920	patients with active UC.
